Clinical Trial: Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT04261023) titled 'Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis' on Jan. 30.

Brief Summary: Phase II, single-centre, open label, two parallel arm cohort randomised controlled trial (RCT) testing abatacept in a population of anti-CCP Ab positive individuals at moderate to high risk of developing IA according to a published risk score, already followed in the observational study 'CCP: Next Generation'

Study Type: Interventional

Condition: Inflammatory Arthritis

Intervention: Drug: Orencia 125 MG Per 1 ML Prefilled Syringe

Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a ma...